Skip to content
FDA Import Alert · 66-41

Ore-An Personal Care Ltd. · West Yorkshire, UNITED KINGDOM

Listed 2012-09-25 · 2 product codes · Source: FDA Import Alert 66-41 · View on FDA

A facility listed under this company name on the FDA Import Alert list as checked on 2026-11-09. See the FDA page for the listed address and products. Full Import Alert list

Firm Record

Orean Personal Care Ltd.

11 findings from 2 inspection documents published by regulators. Each row below says what its date means.

US FDA · 2024-09-10 ~ 2026-11-12

Areas cited

Process validationMaterial and supplier controlDeviation, CAPA, and investigationOther quality systemEquipment and facilityLaboratory and QC controlsComputer system validation

Published inspection documents

Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22). Your quality unit (QU) lacked adequate control over your OTC drug product manufacturing operations and failed to ensure that you had adequate procedures. For example, your QU failed to ensure: Adequate investigations into non-conformances are performed (21 CFR 211.192). Adequate systems for document control and retention are established and followed (e.g., missing, or incomplete batch records, missing testing records and out-of-specification (OOS) investigations) (21 CFR 211.188). Establishment of an adequate ongoing stability program (21 CFR 211.166(a)). Annual product quality reviews are conducted (21 CFR 211.180(e)). In your response, you state that you are in the process of implementing procedures to ensure quality control over your processes. You also state you will perform training for employees. Your response is inadequate. You do not describe how you intend to verify that the procedural updates and employee training are effective. You also do not include the interim measures that you have implemented as part of your remediation to prevent continuing release of products that do not meet CGMP. Your firm’s quality system is inadequate. Your inspectional history indicates that your QU is not able to fully exercise its authority and responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https://www.fda.gov/media/71023/download. In response to this letter, provide: A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to: o A determination of whether procedures used by your firm are robust and appropriate o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices o A complete and final review of each batch and its related information before the QU disposition decision o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products A comprehensive, independent assessment of: o Your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted. o Your documentation systems used throughout manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation. o A CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:  Stability indicating methods  Stability studies for each drug product in its marketed container-closure system before distribution is permitted  An ongoing program in which representative batches of each product are added each year to the program to determine if the self-life claim remains valid  All procedures that describe these and other elements of your remediated stability program A timeline for performing annual product quality review (APQR) for each of your marketed drug products. A plan to ensure that you will complete, and document adequately, product quality reviews at least annually for all drug products; and procedures for investigating, responding to, and correcting any deviations from product quality and safety standards identified as a part of your product quality review findings and risk assessments. CGMP Consultant Recommended Because you failed to correct repeat violations you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance. 2024-09-10 US FDA 3 findingsDeviation, CAPA, and investigation · Process validation and 1 more View the regulator's official source

21 CFR sections cited in FDA inspections

Citations from 1 FDA inspection (2024-03-15) of facilities listed under this company name in FDA's inspection citation data.

As written by FDAInspectionLatest inspection
21 CFR 211.100(a)Absence of Written Procedures12024-03-15
21 CFR 211.192Investigations of discrepancies, failures12024-03-15
21 CFR 211.22(d)Procedures not in writing, fully followed12024-03-15
21 CFR 211.63Equipment Design, Size and Location12024-03-15
21 CFR 211.67(a)Cleaning / Sanitizing / Maintenance12024-03-15
21 CFR 211.80(b)Handling and Storage to Prevent Contamination12024-03-15
21 CFR 211.84(d)(2)Reports of Analysis (Components)12024-03-15

1 site: Orean Personal Care Ltd (Cleckheaton, United Kingdom) · 1 inspection

Source: FDA Data Dashboard - Inspections Citations, as of 2026-11-08. Only inspections with at least one citation are included, and a section cited more than once in one inspection counts once. Only facilities whose name and legal form match this page's documents, and that are listed in a single country, are included.

Other companies with similar findings

Other companies with findings worded closely to this company's. Only documents of the same type are compared.

A record as of publication. Check the agency's own announcements for any later corrective action.

What is included. As collected on 2026-11-15: only documents with a detail page (3 or more findings). See the firm lookup for everything.

Full history of Orean Personal Care Ltd. — including inspection classifications Browse by document Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.